

Galápagos

Galapagos Toledo R&D Roundtable

27 October 2020

Toledo A new paradigm in inflammation & fibrosis

Onno van de Stolpe, CEO

Piet Wigerinck, CSO

Walid Abi-Saab, CMO

Toledo R&D Roundtable | 27 October 2020

Galápagos
Pioneering for patients



Toledo A new paradigm in inflammation & fibrosis

Onno van de Stolpe, CEO
Piet Wigerinck, CSO
Walid Abi-Saab, CMO
Toledo R&D Roundtable | 27 October 2020

Galápagos
Pioneering for patients




Our DNA: seeking out novel modes of action

- Push scientific boundaries
- Follow the science
- Innovative, new methods
- Novel modes of action

5 **Galápagos**

Target discovery approach

Using core GLPG technology → High throughput screening platform → To identify novel targets



7

Galápagos

Our innovative approach with Toledo

1

Target identification

2

Confirmed dual mode of action

3

Broad launching platform

8

Galápagos



Can we make a difference?

% of responders



- Psoriasis
PASI 90
- Other
inflammatory
diseases

Reference: Data on file

9

Galápagos



Our innovative approach with Toledo

1

**Target
identification**

2

**Confirmed
dual mode of
action**


3

**Broad
launching
platform**


11

Galápagos

Restoring the immune imbalance




Dual layer IBD assay






Potential broad application in inflammation



17

Galápagos



**Salt-
Inducible
Kinases**

Galápagos